FRM
ITOS

Fox Run Management’s iTeos Therapeutics ITOS Stock Holding History

Fox Run Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-37,838
Closed -$291K – 1062
2024
Q4 		$291K Buy
37,838
+18,575
+96% +$160K 0.05% 648
2024
Q3 		$197K Buy
19,263
+7,245
+60% +$111K 0.04% 675
2024
Q2 		$178K Sell
12,018
-2,826
-19% -$40.5K 0.03% 685
2024
Q1 		$202K Sell
14,844
-12,913
-47% -$141K 0.04% 631
2023
Q4 		$304K Buy
+27,757
New +$275K 0.08% 487

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fox Run Management's ITOS Position: Q1 2025 in Review

Fox Run Management sold out of iTeos Therapeutics (ITOS) in Q1 2025, closing a stake of 37,838 shares — an estimated $291K sold.

Fox Run Management first reported a position in ITOS in Q4 2023 and held it in 5 quarters. The position peaked at $304K in Q4 2023. 131 funds tracked by Wall St. Rank hold ITOS as of Q1 2025.

  • Fox Run Management reported no remaining iTeos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Fox Run Management sold 37,838 iTeos Therapeutics shares in Q1 2025, an estimated $291K.
  • Fox Run Management first reported a position in iTeos Therapeutics in Q4 2023 and held it in 5 quarters.
  • Fox Run Management's iTeos Therapeutics position peaked at $304K in Q4 2023.
  • 131 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2025.

Based on Fox Run Management's 13F filing for Q1 2025, filed 13 May 2025.